For example, blood levels of CD133+ EVs have been correlated with the presence of metastatic CRC, patient prognosis (overall survival), and objective response rate for first-line systemic therapies (Brocco et al. 2022); and CD147+ EVs have been used as a monitor of the response to therapy in patients with CRC (Moyano et al. 2021). This evidence concerns the gene BSG and colorectal carcinoma.